A Phase 4 interventional study of post operative analgesics in Effect of Drug, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Achieving effective pain control after endodontic treatment is still a disruptive event to all the clinicians. There is a knowledge gap regarding the effect of protease on postoperative pain following root canal treatment, therefore, the efficacy of Trypsin-Chymotrypsin on post endodontic pain was evaluated clinically in a randomized triple-blind trial.
This study approved by the institutional review of board (IRB) of the ethics committee at the Faculty of Dentistry, Ain Shams University, Cairo, Egypt under approval number FDASU-Rec IM012110.
This study design was a prospective, parallel triple blind phase IV randomized clinical trial.
A pilot study was performed on five patients in each group and its results were used for sample size calculation. Based upon the results of the pilot study; the minimum estimated sample size was a total of 52 patients. Sample size was increased to 60 for compensation of the drop-out. Sample size calculation was performed by using G*Power Version 3.1.9.2.
All included patient signed an informed consent prior to start of the study.
Randomization and blinding:60 patients who had the eligibility criteria were allocated randomly according to the ratio of 1:1 to each group. Randomization was performed by using computer software (www.randome.org).
Allocation concealment mechanism: Random sequence generations, allocation concealment and interventions preparation were occurred before starting by the help of one independent person who concealed the allocation sequence from the investigators in opaque and tightly sealed envelope. Before study implementation, this person also divided the medicaments into 60 tightly sealed opaque envelopes contained a treatment with the recommended dose and labeled by one-digit alphabetical symbol (X, Y, Z, R).
Implementation of the study: After root canal treatment, post-operative medicaments were assigned by telephone verification. This independent person informed the operator which drug should be prescribed in the form of X, Y, Z or R to maintain operator blinding. The investigators used the computerized generated randomization protocol for each eligible patient. So, patients were enrolled into each of the groups and prescribed with different post-operative intervention. All pain assessment forms and data were monitored by a trained clinician. He was not a part of the study team.The statistician was also blinded.
Patient history revealed diffuse lingering pulpal pain. Cold sensibility testing with Endo-Ice (1,1,1,2 Tetrafluoroethane; Hygenic Corp) indicated a moderate to severe response. Vitality was matched with the contra lateral as control. The vitality was established clinically by blood observation in the canal. Teeth had no sensitivity to percussion or palpation. Radiographically had normal periapical condition. Endodontic treatment procedures were done by the same operator in the post-graduate clinic of the Endodontic Department of the Faculty of Dentistry, Ain Shams University, Egypt. Patients were assessed by a trained clinician who was not a part of the study team.
85 patients were assessed for the eligibility criteria. 25 individuals were excluded due to different reasons. 60 participants were included. They were randomized into four groups (N = 15).
Group I: (ibuprofen) Participants were given ibuprofen 600 mg 3 times per day for 3 days after each of the three meals.
Group II: (Trypsin-Chymotrypsin) Participants were given (Trypsin 5 mg Chymotrypsin 5 mg3 times per day for 3 days one hour before each of the three meals.
Group III: (ibuprofen + Trypsin Chymotrypsin) Participants were given ibuprofen 600 mg 3 times per day for 3 days after each of the three meals and (Trypsin 5 mg Chymotrypsin 5 mg) 3 times per day for 3 days one hour before each of the three meals.
Group IV: (placebo) Participants were given postoperatively placebo sugar pills 3 times per day for 3 day.
All participant were asked to record their postoperative pain intensity at 6h ,12h ,24h, 48h ,72h following obturation. They also asked to report the occurrence of any side effects.
Data analysis:
Statistical analysis was undertaken with IBM SPSS Statistics. Age difference was analyzed by using one-way ANOVA test. For Pain records, Kruskal-Wallis test for comparison among the four groups, Friedman's test for changes by time intervals in each group and for pair-wise comparisons when Kruskal-Wallis or Friedman's test was significant, Dunn's test was used. Chi-square test was used for qualitative data. The significance level was set at P ≤ 0.05.
Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
Drug: post operative analgesics
Participants were handed Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
Drug: post operative analgesics
Participants were handed Brufen (Ibuprofen) (Abbott chemical laboratories, Advil, USA) 600 mg 3 times daily for 3 days after meals and Ambezim G (Trypsin 5 mg Chymotrypsin 5 mg) (Global Napi Pharmaceutical Company, Giza, Egypt) 3 times daily for 3 days one hour before meals in tightly sealed envelope with an included written paper contained the instruction for dose administration.
Drug: post operative analgesics
Participants were handed postoperatively sugar pills (Placebo pills) (Department of pharmaceutics \& industrial pharmacy at Faculty of pharmacy Ain Shams University, Cairo, Egypt) 3 times daily for 3 days in tightly sealed envelope with an included written paper contained the instruction for dose administration.
Drug: post operative analgesics
post-operative pain killer
Also known as: pain control drug
Effect of Trypsin-Chymotrypsin on Post-operative Pain After Single Endodontic Treatment in Teeth With Symptomatic Irreversible Pulpitis
analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.
Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
Synergistic Effect With NSAIDS
analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.
Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
Reported Side Effect
assessed by Passive surveillance of harm. It depends on adverse effects reported by the participants.
Time frame: from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals)
| Milestone | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) |
|---|---|---|---|---|
| Started | 15 | 15 | 15 | 15 |
| Completed | 15 | 15 | 15 | 15 |
| Not completed | 0 | 0 | 0 | 0 |
analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.
| score on a scale | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) |
|---|---|---|---|---|
| after 6 hours follow up | 3.47 ± 1.55 | 3.53 ± 1.46 | 2.93 ± 1.33 | 6.13 ± 0.64 |
| after 12 hours follow up | 2 ± 1.41 | 1.87 ± 1.51 | 1.4 ± 0.91 | 4.47 ± 0.64 |
| after 24 hours follow up | 0.87 ± 1.06 | 0.8 ± 1.08 | 0.2 ± 0.41 | 3.4 ± 0.74 |
| after 48 hours follow up | 0 ± 0 | 0.13 ± 0.52 | 0 ± 0 | 2.47 ± 0.64 |
| after 72 hours follow up | 0 ± 0 | 0.13 ± 0.52 | 0 ± 0 | 1.2 ± 0.77 |
analgesic effect assessed by numerical rating scale. The minimum score value is zero. The maximum score value is ten. Maximum scores indicate the worst possible outcome.
| score on a scale | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) |
|---|---|---|---|---|
| after 6 hours follow up | 3.47 ± 1.55 | 3.53 ± 1.46 | 2.93 ± 1.33 | 6.13 ± 0.64 |
| after 12 hours follow up | 2 ± 1.41 | 1.87 ± 1.51 | 1.4 ± 0.91 | 4.47 ± 0.64 |
| after 24 hours follow up | 0.87 ± 1.06 | 0.8 ± 1.08 | 0.2 ± 0.41 | 3.4 ± 0.74 |
| after 48 hours follow up | 0 ± 0 | 0.13 ± 0.52 | 0 ± 0 | 2.47 ± 0.64 |
| after 72 hours follow up | 0 ± 0 | 0.13 ± 0.52 | 0 ± 0 | 1.2 ± 0.77 |
assessed by Passive surveillance of harm. It depends on adverse effects reported by the participants.
| reported side effects | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) |
|---|---|---|---|---|
| after 6 hours | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| after 12 hours | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| after 24 hours | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| after 48 hours | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| after 72 hours | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Collected over from 6 hours following drug intake after obturation to 72 hours (start with 6 hours first interval then at 12 hours intervals). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen (Brufen) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Placebo Pills (Sugar Pills) | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Age, Continuous(years) | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) | Total |
|---|---|---|---|---|---|
| Mean | 27.5 ± 8 | 27.8 ± 8 | 27.9 ± 8.1 | 28 ± 7.7 | 27.8 ± 7.9 |
| Sex: Female, Male(Participants) | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) | Total |
|---|---|---|---|---|---|
| Female | 8 | 7 | 9 | 8 | 32 |
| Male | 7 | 8 | 6 | 7 | 28 |
| Race/Ethnicity, Customized(participants) | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) | Total |
|---|---|---|---|---|---|
| Egyptian | 15 | 15 | 15 | 15 | 60 |
| Region of Enrollment(participants) | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) | Total |
|---|---|---|---|---|---|
| Egypt | 15 | 15 | 15 | 15 | 60 |
| pre-operative pain scores(units on a scale) | Ibuprofen (Brufen) | Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Ibuprofen (Brufen) + Trypsin 5 mg Chymotrypsin 5 mg (Ambezim G) | Placebo Pills (Sugar Pills) | Total |
|---|---|---|---|---|---|
| Mean | 8.4 ± 0.63 | 8.53 ± 1.13 | 8.13 ± 1.36 | 8.73 ± 0.8 | 8.4 ± 0.98 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University